Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) will participate in investor conferences in March, including Raymond James 45th Annual Institutional Investors Conference and TD Cowen 44th Annual Health Care Conference. The events will have live webcasts and audio archives accessible through the Natera website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
-
Rhea-AI Summary
Natera, Inc. (NTRA) reports strong financial results for Q4 2023, showing significant revenue growth and test volume increases. The company achieved total revenues of $311.1 million in Q4 2023, up 43.2% from the previous year, with product revenues growing by 44.3%. Natera processed approximately 2,496,100 tests in 2023, a 20.8% increase from 2022. The company's gross margins improved to 51.4% in Q4 2023. Natera expects 2024 revenue of $1.32 billion-$1.35 billion and continues to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
-
Rhea-AI Summary
Natera, Inc. (NTRA) progresses in patent infringement litigation against CareDx with a $96.3 million jury verdict in lost profits and past royalties. The U.S. District Court will decide on future royalties for ongoing AlloSure testing. Discovery and briefing to continue till summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
Rhea-AI Summary
Natera, Inc. (NTRA) announces that its Signatera MRD test has met coverage requirements from CMS in new indications for ovarian and breast cancer. The test has shown promising results in detecting recurrence early and predicting therapy response, potentially improving outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
-
Rhea-AI Summary
Natera, Inc. (NTRA) to release Q4 and year-end 2023 financial results on Feb. 28, 2024. Conference call and webcast to follow. Details provided for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced a study validating its MRD test, Signatera, in endometrial cancer. The study showed that patients who tested Signatera MRD-positive experienced significantly higher rates of recurrence, making Signatera a powerful post-surgical biomarker of recurrence risk for patients with endometrial cancer. The potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer was demonstrated in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
Rhea-AI Summary
Natera, Inc. (NTRA) announced a new study demonstrating the effectiveness of its Signatera MRD test in detecting recurrence early in patients with resected stage I-II non-small cell lung cancer. The study showed that clinical management was altered in 100% of patients with a Signatera positive result, highlighting the potential of this test in risk stratification. With NSCLC accounting for 81% of all lung cancer diagnoses in the U.S., this study has significant implications for patient care and cancer management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
-
Rhea-AI Summary
Natera, Inc. (NTRA) has won a patent infringement case against CareDx, Inc., with the jury awarding Natera $83.7 million in lost profits and $12.6 million in past royalties. The jury also found that all asserted claims of Natera's patents are valid and provided an advisory verdict that all asserted claims are valid under 35 U.S.C. Sec. 101. Further proceedings will determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe Natera's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™ The first study, AMPLIFY-201, evaluated the ELI-002 cancer vaccine and enrolled 25 patients with solid tumors. Results showed that 21 patients had Signatera-positive status after locoregional treatment, and tumor biomarker responses were observed in 84% of patients. The study highlights the potential utility of ctDNA as a reliable surrogate biomarker for treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
Natera Inc
Nasdaq:NTRA
NTRA Rankings
NTRA Stock Data
20.88B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
United States
AUSTIN